Ketamine is under clinical development by Neurocentrx Pharma and currently in Phase I for Bipolar Disorder (Manic Depression). According to GlobalData, Phase I drugs for Bipolar Disorder (Manic Depression) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ketamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ketamine overview

Ketamine is under development for the treatment of major depressive disorder, treatment-resistant depression (TRD) and bipolar depression. The drug candidate is administered through oral route formulated as a immediate release capsule. It acts by targeting glutamate ionotropic receptor AMPA type subunit (AMPA). It was also under development for the treatment of cancer pain.

Neurocentrx Pharma overview

Neurocentrx Pharma (Neurocentrx) is a biotech company that carries out the development of medicines for the treatment of various neurological diseases. The company offers oral ketamine formulations such as Keticap-IR and Keticap-AD. It also provides drug candidates in oral form to treat neurodegenerative diseases, mental health and mood disorders, psychiatric, and complex pain management in cancer and palliative care. Neurocentrx markets its products under the brand name Keticap. The company also carries out various phases of clinical trials. It collaborates with charities, venture philanthropists, patients, clinicians and corporate investors for new product ideas and development. Neurocentrx is headquartered in Edinburgh, Scotland, the UK.

For a complete picture of Ketamine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.